Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Equity Income (2016 - 2020)

Ligand Pharmaceuticals' Equity Income history spans 6 years, with the latest figure at -$25.5 million for Q1 2020.

  • For Q1 2020, Equity Income fell 247.2% year-over-year to -$25.5 million; the TTM value through Mar 2020 reached -$39.9 million, down 192.66%, while the annual FY2019 figure was $2.9 million, 93.94% down from the prior year.
  • Equity Income for Q1 2020 was -$25.5 million at Ligand Pharmaceuticals, down from $8.5 million in the prior quarter.
  • Across five years, Equity Income topped out at $59.9 million in Q3 2018 and bottomed at -$74.0 million in Q4 2018.
  • The 5-year median for Equity Income is -$1.2 million (2017), against an average of $180764.7.
  • The largest YoY upside for Equity Income was 5975.47% in 2018 against a maximum downside of 1758.18% in 2018.
  • A 5-year view of Equity Income shows it stood at -$9.0 million in 2016, then soared by 149.64% to $4.5 million in 2017, then tumbled by 1758.18% to -$74.0 million in 2018, then skyrocketed by 111.46% to $8.5 million in 2019, then tumbled by 400.19% to -$25.5 million in 2020.
  • Per Business Quant, the three most recent readings for LGND's Equity Income are -$25.5 million (Q1 2020), $8.5 million (Q4 2019), and -$10.5 million (Q3 2019).